Labcorp (NYSE: LH) recently received a number of ratings updates from brokerages and research firms:
- 11/5/2026 – Labcorp was upgraded by HSBC from “hold” to “buy”. They now have a $410.00 price target on the stock.
- 10/29/2026 – Labcorp had its “hold” rating reaffirmed by Deutsche Bank. They now have a $355.00 price target on the stock.
- 10/29/2026 – Labcorp had its price target raised by UBS Group from $380.00 to $420.00. They now have a “buy” rating on the stock.
- 10/29/2026 – Labcorp had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $388.00 price target on the stock.
- 10/29/2026 – Labcorp had its price target raised by Truist Financial from $365.00 to $395.00. They now have a “buy” rating on the stock.
- 10/29/2026 – Labcorp had its price target raised by Robert W. Baird from $361.00 to $396.00. They now have an “outperform” rating on the stock.
- 10/28/2026 – Labcorp had its price target raised by Barclays from $330.00 to $380.00. They now have an “equal weight” rating on the stock.
- 10/28/2026 – Labcorp was given a new $410.00 price target by Leerink Partners.
- 10/21/2026 – Labcorp was upgraded by Weiss Ratings from “buy (b+)” to “buy (a-)”.
- 10/6/2026 – Labcorp was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
- 9/21/2026 – Labcorp had its price target raised by Truist Financial from $350.00 to $365.00. They now have a “buy” rating on the stock.
Labcorp Price Performance
LH stock traded down $2.26 during midday trading on Thursday, reaching $368.52. The company had a trading volume of 193,303 shares, compared to its average volume of 696,074. The firm has a 50-day moving average price of $332.38 and a 200-day moving average price of $294.09. The company has a market capitalization of $29.92 billion, a P/E ratio of 30.23, a P/E/G ratio of 2.08 and a beta of 0.86. Labcorp Holdings Inc. has a 1 year low of $245.00 and a 1 year high of $375.10. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.41 and a quick ratio of 1.22.
Labcorp (NYSE:LH – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The medical research company reported $4.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.64 by $0.14. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.76 billion. Labcorp had a net margin of 6.88% and a return on equity of 17.13%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.18 EPS. On average, research analysts anticipate that Labcorp Holdings Inc. will post 18.51 earnings per share for the current fiscal year.
Labcorp Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Tuesday, November 24th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 0.8%. The ex-dividend date is Tuesday, November 24th. Labcorp’s dividend payout ratio is presently 23.63%.
Insider Buying and Selling at Labcorp
In other news, EVP Bryan Vaughn sold 306 shares of Labcorp stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $353.70, for a total value of $108,232.20. Following the transaction, the executive vice president owned 6,845 shares in the company, valued at approximately $2,421,076.50. The trade was a 4.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Brian Caveney sold 2,000 shares of the stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $372.04, for a total value of $744,080.00. Following the sale, the executive vice president owned 34,562 shares of the company’s stock, valued at $12,858,446.48. This represents a 5.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 3,749 shares of company stock valued at $1,377,699. Corporate insiders own 0.84% of the company’s stock.
Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.
Further Reading
- Five stocks we like better than Labcorp
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
- 3 Niche ETFs Are Beating the S&P 500, and Their Strategies Are Anything but Typical
Receive News & Ratings for Labcorp Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.
